Global Adgre1 Market Report (2025–2036)
Market Overview
The global Adgre1 (also known as F4/80 antigen, a macrophage marker) market was valued at USD xxxx million in 2025 and is projected to reach USD xxxx million by 2036, growing at a CAGR of xx%. Adgre1 antibodies and reagents are widely used in immunology, oncology, and bioscience research to study macrophage biology, immune responses, and disease progression. Rising demand for advanced cell biology tools, expansion of biopharmaceutical R&D, and increasing focus on immunotherapy are driving market growth.
Impact of COVID-19
The pandemic disrupted laboratory operations and supply chains in 2020, slowing research activities. However, COVID-19 accelerated demand for immunology-related assays, including macrophage markers like Adgre1, as researchers explored immune responses to viral infections. Post-pandemic recovery has been marked by increased investments in biomedical research, boosting adoption of Adgre1 reagents.
Market Segmentation
By Type
- Above 90% Purity – suitable for general laboratory applications.
- Above 95% Purity – used in advanced immunology and oncology research.
- Above 99% Purity – preferred in biopharmaceutical and clinical-grade applications.
- Others – customized formulations and recombinant Adgre1 proteins.
By Application
- Hospitals – diagnostic and translational research applications.
- Bioscience Research Institutions – academic and government labs studying macrophage biology.
- Others – contract research organizations (CROs), biotech firms, and diagnostic kit manufacturers.
Regional Analysis
- North America: Largest market; strong demand from biopharma companies and advanced research institutions.
- Europe: Significant growth; Germany, U.K., and France lead adoption with strong biotech clusters.
- Asia-Pacific: Fastest-growing region; China, India, and Japan expanding biomedical research and pharmaceutical manufacturing.
- South America: Brazil and Argentina showing growth in oncology and immunology research.
- Middle East & Africa: Emerging demand; increasing investments in healthcare and life sciences infrastructure.
Key Players
- Aviva Systems Biology Corporation (U.S.)
- Atlas Antibodies (Sweden)
- Abbexa Ltd (U.K.)
- Boster Biological Technology (U.S.)
- Biobyt (U.K.)
- Bio-Rad Laboratories (U.S.)
- Bioss Antibodies (U.S.)
- Biosensis (U.S.)
- BioLegend (U.S.)
- Genetex (U.S.)
- Lifespan Biosciences (U.S.)
- Novus Biologicals (U.S.)
- Proteintech (U.S.)
- ProSci (U.S.)
- ProteoGenix (France)
- Stemcell Technologies (Canada)
- Rockland Immunochemicals (U.S.)
- R&D Systems (U.S.)
- St John’s Laboratory Ltd (U.K.)
- Thermo Fisher Scientific (U.S.)
- USBiological (U.S.)
Additional Players:
- Cell Signaling Technology (U.S.)
- Santa Cruz Biotechnology (U.S.)
- Abnova Corporation (Taiwan)
- Creative Diagnostics (U.S.)
- Sino Biological (China)
- GenScript Biotech (China/U.S.)
- OriGene Technologies (U.S.)
Porter’s Five Forces
- Threat of New Entrants – Moderate; requires R&D investment and distribution networks.
- Bargaining Power of Suppliers – Moderate; specialized reagents and raw materials influence costs.
- Bargaining Power of Buyers – High; research institutions and pharma companies demand cost-effective, high-quality Adgre1 reagents.
- Threat of Substitutes – Moderate; alternatives include other macrophage markers and molecular assays.
- Industry Rivalry – High; global players compete on innovation, pricing, and distribution.
SWOT Analysis
Strengths:
- Essential role in macrophage and immunology research
- Wide applications across oncology, immunotherapy, and infectious disease studies
- Established global suppliers with strong distribution
Weaknesses:
- High production costs for recombinant proteins
- Dependence on research funding cycles
- Limited awareness in emerging markets
Opportunities:
- Growth in personalized medicine and immunotherapy research
- Expansion in Asia-Pacific and Middle East markets
- Rising demand for macrophage markers in drug development
Threats:
- Competition from alternative biomarkers
- Regulatory hurdles in clinical applications
- Supply chain vulnerabilities
Trend Analysis
- Immunotherapy Expansion: Increasing use of macrophage markers in cancer and autoimmune disease research.
- Recombinant Protein Growth: Rising demand for high-purity Adgre1 proteins.
- Digital Integration: AI-driven bioinformatics supporting immune pathway analysis.
- Global Collaborations: Partnerships between biotech firms and research institutions.
- Sustainability: Eco-friendly production and packaging of reagents.
Drivers & Challenges
Drivers:
- Rising prevalence of cancer and autoimmune diseases
- Increasing demand for immunology-related biomarkers
- Technological advancements in protein engineering
- Expansion of biopharmaceutical R&D
Challenges:
- High costs of production and validation
- Regulatory complexity in clinical applications
- Competition from alternative diagnostic technologies
- Limited skilled workforce in specialized labs
Value Chain Analysis
- Raw Materials: Cell lines, reagents, and consumables.
- Manufacturing: Recombinant Adgre1 production, purification, and validation.
- Distribution: Hospitals, research institutions, biopharma companies, and CROs.
- End Users: Researchers, clinicians, and diagnostic developers.
- After-Sales Services: Technical support, assay optimization, and training.
Quick Recommendations for Stakeholders
- Manufacturers: Invest in recombinant Adgre1 proteins with higher purity levels.
- Healthcare Providers: Expand adoption of Adgre1 assays in oncology and immunology diagnostics.
- Policy Makers: Support funding for immunology-related research and regulate clinical-grade Adgre1 applications.
- Investors: Focus on Asia-Pacific and Europe for high-growth opportunities.
- Research Institutions: Collaborate with biotech firms to accelerate innovation in macrophage biology studies.
Explore more reports here-
https://westernmarketresearch.com/reports
1. Market Overview of Adgre1
1.1 Adgre1 Market Overview
1.1.1 Adgre1 Product Scope
1.1.2 Market Status and Outlook
1.2 Adgre1 Market Size by Regions: 2015 VS 2021 VS 2026
1.3 Adgre1 Historic Market Size by Regions
1.4 Adgre1 Forecasted Market Size by Regions
1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth
1.5.1 North America
1.5.2 East Asia
1.5.3 Europe
1.5.4 South Asia
1.5.5 Southeast Asia
1.5.6 Middle East
1.5.7 Africa
1.5.8 Oceania
1.5.9 South America
1.5.10 Rest of the World
1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact Adgre1 Sales Market by Type
2.1 Global Adgre1 Historic Market Size by Type
2.2 Global Adgre1 Forecasted Market Size by Type
2.3 Above 90%
2.4 Above 95%
2.5 Above 99%
2.6 Others
3. Covid-19 Impact Adgre1 Sales Market by Application
3.1 Global Adgre1 Historic Market Size by Application
3.2 Global Adgre1 Forecasted Market Size by Application
3.3 Hospitals
3.4 Bioscience Research Institutions
3.5 Others
4. Covid-19 Impact Market Competition by Manufacturers
4.1 Global Adgre1 Production Capacity Market Share by Manufacturers
4.2 Global Adgre1 Revenue Market Share by Manufacturers
4.3 Global Adgre1 Average Price by Manufacturers
5. Company Profiles and Key Figures in Adgre1 Business
5.1 Aviva Systems Biology Corporation(US)
5.1.1 Aviva Systems Biology Corporation(US) Company Profile
5.1.2 Aviva Systems Biology Corporation(US) Adgre1 Product Specification
5.1.3 Aviva Systems Biology Corporation(US) Adgre1 Production Capacity, Revenue, Price and Gross Margin
5.2 Atlas Antibodies(SE)
5.2.1 Atlas Antibodies(SE) Company Profile
5.2.2 Atlas Antibodies(SE) Adgre1 Product Specification
5.2.3 Atlas Antibodies(SE) Adgre1 Production Capacity, Revenue, Price and Gross Margin
5.3 Abbexa Ltd(UK)
5.3.1 Abbexa Ltd(UK) Company Profile
5.3.2 Abbexa Ltd(UK) Adgre1 Product Specification
5.3.3 Abbexa Ltd(UK) Adgre1 Production Capacity, Revenue, Price and Gross Margin
5.4 Boster Biological Technology(US)
5.4.1 Boster Biological Technology(US) Company Profile
5.4.2 Boster Biological Technology(US) Adgre1 Product Specification
5.4.3 Boster Biological Technology(US) Adgre1 Production Capacity, Revenue, Price and Gross Margin
5.5 Biobyt(UK)
5.5.1 Biobyt(UK) Company Profile
5.5.2 Biobyt(UK) Adgre1 Product Specification
5.5.3 Biobyt(UK) Adgre1 Production Capacity, Revenue, Price and Gross Margin
5.6 Bio-Rad(US)
5.6.1 Bio-Rad(US) Company Profile
5.6.2 Bio-Rad(US) Adgre1 Product Specification
5.6.3 Bio-Rad(US) Adgre1 Production Capacity, Revenue, Price and Gross Margin
5.7 Bioss Antibodies(US)
5.7.1 Bioss Antibodies(US) Company Profile
5.7.2 Bioss Antibodies(US) Adgre1 Product Specification
5.7.3 Bioss Antibodies(US) Adgre1 Production Capacity, Revenue, Price and Gross Margin
5.8 Biosensis(US)
5.8.1 Biosensis(US) Company Profile
5.8.2 Biosensis(US) Adgre1 Product Specification
5.8.3 Biosensis(US) Adgre1 Production Capacity, Revenue, Price and Gross Margin
5.9 BioLegend(US)
5.9.1 BioLegend(US) Company Profile
5.9.2 BioLegend(US) Adgre1 Product Specification
5.9.3 BioLegend(US) Adgre1 Production Capacity, Revenue, Price and Gross Margin
5.10 Genetex(US)
5.10.1 Genetex(US) Company Profile
5.10.2 Genetex(US) Adgre1 Product Specification
5.10.3 Genetex(US) Adgre1 Production Capacity, Revenue, Price and Gross Margin
5.11 Lifespan Biosciences(US)
5.11.1 Lifespan Biosciences(US) Company Profile
5.11.2 Lifespan Biosciences(US) Adgre1 Product Specification
5.11.3 Lifespan Biosciences(US) Adgre1 Production Capacity, Revenue, Price and Gross Margin
5.12 Novus Biologicals(US)
5.12.1 Novus Biologicals(US) Company Profile
5.12.2 Novus Biologicals(US) Adgre1 Product Specification
5.12.3 Novus Biologicals(US) Adgre1 Production Capacity, Revenue, Price and Gross Margin
5.13 Proteintech(US)
5.13.1 Proteintech(US) Company Profile
5.13.2 Proteintech(US) Adgre1 Product Specification
5.13.3 Proteintech(US) Adgre1 Production Capacity, Revenue, Price and Gross Margin
5.14 ProSci(US)
5.14.1 ProSci(US) Company Profile
5.14.2 ProSci(US) Adgre1 Product Specification
5.14.3 ProSci(US) Adgre1 Production Capacity, Revenue, Price and Gross Margin
5.15 ProteoGenix(FR)
5.15.1 ProteoGenix(FR) Company Profile
5.15.2 ProteoGenix(FR) Adgre1 Product Specification
5.15.3 ProteoGenix(FR) Adgre1 Production Capacity, Revenue, Price and Gross Margin
5.16 Stemcell(CA)
5.16.1 Stemcell(CA) Company Profile
5.16.2 Stemcell(CA) Adgre1 Product Specification
5.16.3 Stemcell(CA) Adgre1 Production Capacity, Revenue, Price and Gross Margin
5.17 Rockland(US)
5.17.1 Rockland(US) Company Profile
5.17.2 Rockland(US) Adgre1 Product Specification
5.17.3 Rockland(US) Adgre1 Production Capacity, Revenue, Price and Gross Margin
5.18 R&D Systems(US)
5.18.1 R&D Systems(US) Company Profile
5.18.2 R&D Systems(US) Adgre1 Product Specification
5.18.3 R&D Systems(US) Adgre1 Production Capacity, Revenue, Price and Gross Margin
5.19 St John's Laboratory Ltd(UK)
5.19.1 St John's Laboratory Ltd(UK) Company Profile
5.19.2 St John's Laboratory Ltd(UK) Adgre1 Product Specification
5.19.3 St John's Laboratory Ltd(UK) Adgre1 Production Capacity, Revenue, Price and Gross Margin
5.20 Thermo Fisher Scientific(US)
5.20.1 Thermo Fisher Scientific(US) Company Profile
5.20.2 Thermo Fisher Scientific(US) Adgre1 Product Specification
5.20.3 Thermo Fisher Scientific(US) Adgre1 Production Capacity, Revenue, Price and Gross Margin
5.21 USBiological(US)
5.21.1 USBiological(US) Company Profile
5.21.2 USBiological(US) Adgre1 Product Specification
5.21.3 USBiological(US) Adgre1 Production Capacity, Revenue, Price and Gross Margin
6. North America
6.1 North America Adgre1 Market Size
6.2 North America Adgre1 Key Players in North America
6.3 North America Adgre1 Market Size by Type
6.4 North America Adgre1 Market Size by Application
7. East Asia
7.1 East Asia Adgre1 Market Size
7.2 East Asia Adgre1 Key Players in North America
7.3 East Asia Adgre1 Market Size by Type
7.4 East Asia Adgre1 Market Size by Application
8. Europe
8.1 Europe Adgre1 Market Size
8.2 Europe Adgre1 Key Players in North America
8.3 Europe Adgre1 Market Size by Type
8.4 Europe Adgre1 Market Size by Application
9. South Asia
9.1 South Asia Adgre1 Market Size
9.2 South Asia Adgre1 Key Players in North America
9.3 South Asia Adgre1 Market Size by Type
9.4 South Asia Adgre1 Market Size by Application
10. Southeast Asia
10.1 Southeast Asia Adgre1 Market Size
10.2 Southeast Asia Adgre1 Key Players in North America
10.3 Southeast Asia Adgre1 Market Size by Type
10.4 Southeast Asia Adgre1 Market Size by Application
11. Middle East
11.1 Middle East Adgre1 Market Size
11.2 Middle East Adgre1 Key Players in North America
11.3 Middle East Adgre1 Market Size by Type
11.4 Middle East Adgre1 Market Size by Application
12. Africa
12.1 Africa Adgre1 Market Size
12.2 Africa Adgre1 Key Players in North America
12.3 Africa Adgre1 Market Size by Type
12.4 Africa Adgre1 Market Size by Application
13. Oceania
13.1 Oceania Adgre1 Market Size
13.2 Oceania Adgre1 Key Players in North America
13.3 Oceania Adgre1 Market Size by Type
13.4 Oceania Adgre1 Market Size by Application
14. South America
14.1 South America Adgre1 Market Size
14.2 South America Adgre1 Key Players in North America
14.3 South America Adgre1 Market Size by Type
14.4 South America Adgre1 Market Size by Application
15. Rest of the World
15.1 Rest of the World Adgre1 Market Size
15.2 Rest of the World Adgre1 Key Players in North America
15.3 Rest of the World Adgre1 Market Size by Type
15.4 Rest of the World Adgre1 Market Size by Application
16 Adgre1 Market Dynamics
16.1 Covid-19 Impact Market Top Trends
16.2 Covid-19 Impact Market Drivers
16.3 Covid-19 Impact Market Challenges
16.4 Porter
Market Segmentation
By Type
- Above 90% Purity – suitable for general laboratory applications.
- Above 95% Purity – used in advanced immunology and oncology research.
- Above 99% Purity – preferred in biopharmaceutical and clinical-grade applications.
- Others – customized formulations and recombinant Adgre1 proteins.
By Application
- Hospitals – diagnostic and translational research applications.
- Bioscience Research Institutions – academic and government labs studying macrophage biology.
- Others – contract research organizations (CROs), biotech firms, and diagnostic kit manufacturers.
Regional Analysis
- North America: Largest market; strong demand from biopharma companies and advanced research institutions.
- Europe: Significant growth; Germany, U.K., and France lead adoption with strong biotech clusters.
- Asia-Pacific: Fastest-growing region; China, India, and Japan expanding biomedical research and pharmaceutical manufacturing.
- South America: Brazil and Argentina showing growth in oncology and immunology research.
- Middle East & Africa: Emerging demand; increasing investments in healthcare and life sciences infrastructure.
Key Players
- Aviva Systems Biology Corporation (U.S.)
- Atlas Antibodies (Sweden)
- Abbexa Ltd (U.K.)
- Boster Biological Technology (U.S.)
- Biobyt (U.K.)
- Bio-Rad Laboratories (U.S.)
- Bioss Antibodies (U.S.)
- Biosensis (U.S.)
- BioLegend (U.S.)
- Genetex (U.S.)
- Lifespan Biosciences (U.S.)
- Novus Biologicals (U.S.)
- Proteintech (U.S.)
- ProSci (U.S.)
- ProteoGenix (France)
- Stemcell Technologies (Canada)
- Rockland Immunochemicals (U.S.)
- R&D Systems (U.S.)
- St John’s Laboratory Ltd (U.K.)
- Thermo Fisher Scientific (U.S.)
- USBiological (U.S.)
Additional Players:
- Cell Signaling Technology (U.S.)
- Santa Cruz Biotechnology (U.S.)
- Abnova Corporation (Taiwan)
- Creative Diagnostics (U.S.)
- Sino Biological (China)
- GenScript Biotech (China/U.S.)
- OriGene Technologies (U.S.)
